These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
305 related items for PubMed ID: 1531825
1. A double-blind comparison of paroxetine, imipramine, and placebo in major depression. Shrivastava RK, Shrivastava SH, Overweg N, Blumhardt CL. J Clin Psychiatry; 1992 Feb; 53 Suppl():48-51. PubMed ID: 1531825 [Abstract] [Full Text] [Related]
7. The efficacy and safety of paroxetine compared with placebo in outpatients with major depression. Rickels K, Amsterdam J, Clary C, Fox I, Schweizer E, Weise C. J Clin Psychiatry; 1992 Feb; 53 Suppl():30-2. PubMed ID: 1531820 [Abstract] [Full Text] [Related]
8. The safety and efficacy of paroxetine compared with placebo in a double-blind trial of depressed outpatients. Claghorn JL. J Clin Psychiatry; 1992 Feb; 53 Suppl():33-5. PubMed ID: 1531821 [Abstract] [Full Text] [Related]
9. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. Schweizer E, Feighner J, Mandos LA, Rickels K. J Clin Psychiatry; 1994 Mar; 55(3):104-8. PubMed ID: 8071246 [Abstract] [Full Text] [Related]
11. A double-blind placebo-controlled study of fluvoxamine and imipramine in depression. Dominguez RA, Goldstein BJ, Jacobson AF, Steinbook RM. J Clin Psychiatry; 1985 Mar; 46(3):84-7. PubMed ID: 3918993 [Abstract] [Full Text] [Related]
12. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. Dunner DL, Cohn JB, Walshe T, Cohn CK, Feighner JP, Fieve RR, Halikas JP, Hartford JT, Hearst ED, Settle EC. J Clin Psychiatry; 1992 Feb; 53 Suppl():57-60. PubMed ID: 1531827 [Abstract] [Full Text] [Related]
13. The short- and long-term efficacy of paroxetine HCl: A. Data from a 6-week double-blind parallel design trial vs. imipramine and placebo. Peselow ED, Filippi AM, Goodnick P, Barouche F, Fieve RR. Psychopharmacol Bull; 1989 Feb; 25(2):267-71. PubMed ID: 2532373 [No Abstract] [Full Text] [Related]
14. Nefazodone: aspects of efficacy. Rickels K, Robinson DS, Schweizer E, Marcus RN, Roberts DL. J Clin Psychiatry; 1995 Feb; 56 Suppl 6():43-6. PubMed ID: 7649973 [Abstract] [Full Text] [Related]
16. Paroxetine in the treatment of depression: a comparison with imipramine and placebo. Feighner JP, Boyer WF. Acta Psychiatr Scand Suppl; 1989 Feb; 350():125-9. PubMed ID: 2530763 [Abstract] [Full Text] [Related]
17. Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies. Chouinard G, Saxena BM, Nair NP, Kutcher SP, Bakish D, Bradwejn J, Kennedy SH, Sharma V, Remick RA, Kukha-Mohamad SA. Clin Neuropharmacol; 1993 Feb; 16 Suppl 2():S51-4. PubMed ID: 8313397 [Abstract] [Full Text] [Related]
18. Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression. Cohn CK, Robinson DS, Roberts DL, Schwiderski UE, O'Brien K, Ieni JR. J Clin Psychiatry; 1996 Feb; 57 Suppl 2():15-8. PubMed ID: 8626358 [Abstract] [Full Text] [Related]
19. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I. Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385 [Abstract] [Full Text] [Related]
20. Response of anxiety and agitation symptoms during nefazodone treatment of major depression. Fawcett J, Marcus RN, Anton SF, O'Brien K, Schwiderski U. J Clin Psychiatry; 1995 Dec; 56 Suppl 6():37-42. PubMed ID: 7649972 [Abstract] [Full Text] [Related] Page: [Next] [New Search]